BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 25834799)

  • 1. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
    Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
    Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.
    Lee HW; Kwon JC; Oh IS; Chang HY; Cha YJ; Choi IS; Kim HJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5348-56. PubMed ID: 26100697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
    Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 11. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
    Park JW; Kwak KM; Kim SE; Jang MK; Suk KT; Kim DJ; Park SH; Lee MS; Kim HS; Park CK
    BMC Gastroenterol; 2017 Mar; 17(1):39. PubMed ID: 28279168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial.
    Yim HJ; Kim IH; Suh SJ; Jung YK; Kim JH; Seo YS; Yeon JE; Kim CW; Kwon SY; Park SH; Lee MS; Um SH; Byun KS
    J Viral Hepat; 2018 Nov; 25(11):1321-1330. PubMed ID: 29772084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B.
    Chon YE; Kim SU; Lee CK; Heo J; Kim JK; Yoon KT; Cho M; Lee KS; Kim DH; Choi EH; Park JY; Kim DY; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2011; 16(4):469-77. PubMed ID: 21685534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.
    Kim HJ; Cho YK; Jeon WK; Kim BI
    Clin Mol Hepatol; 2017 Dec; 23(4):323-330. PubMed ID: 28870025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
    Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
    Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.